MedMira Inc., the global market leader in rapid flow-through diagnostic technology, has received approval from the US FDA to provide new features in its Reveal G2 Rapid HIV-1 Antibody Test. These enhancements will continue to heighten the competitiveness of Reveal G2 in the marketplace and further increase customer satisfaction.

This latest FDA approval enables MedMira to provide external control material with an extended shelf-life and additional flexibility, answering the emerging challenges and needs of the market. US laboratory professionals are subject to strict quality control requirements, and MedMira's enhancement to the external controls will improve cost-effectiveness and versatility for the customer.

Reveal G2 is currently the fastest rapid HIV test, at only 3-minutes, available in the United States and according to an independent study by the US Centres for Disease Control and Prevention (CDC), is the number one rapid HIV test used in US hospitals.

Over 180,000 HIV testing locations, including laboratories and hospitals, conduct an estimated 28 million HIV tests each year in the United States.